- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946068
Aleniglipron Renal Impairment Study
November 13, 2026 updated by: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on Aleniglipron Pharmacokinetics
The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical Director
- Phone Number: 650-457-1959
- Email: GSBRClinicalTrials@Structuretx.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Research Site
-
Contact:
- Medical Director
- Phone Number: 650-457-1959
- Email: GSBRClinicalTrials@Structuretx.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening.
- BMI ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg
- Understands the study procedures in the ICF and is willing and able to comply with the protocol and communicate effectively with study personnel.
- Group 1 only: Participant has severe RI maintained on stable regimen of high-flux HD at least 3 times per week for at least 3 months
- Group 2 only: Has normal renal function with eGFR ≥ 90 mL/min
Exclusion Criteria:
- History or presence of alcohol or drug abuse within the past 6 months prior to the dosing.
- History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
- Female participant with a positive pregnancy test at screening or at first check-in or who is lactating or breastfeeding
- Has taken medications intended to promote weight loss within 3 months or 5 half-lives, whichever is longer, prior to screening, including, but not limited to GLP-1 RAs.
- Received an investigational product in another clinical study within 30 days or 5 half-lives (if known) prior to first dosing, whichever is longer.
- Has a history or presence of clinically significant medical or psychiatric condition or disease, any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1: Participants with severe renal impairment on intermittent hemodialysis
Aleniglipron administered orally |
Administered orally |
|
Experimental: Group 2: Participants with normal renal function
Aleniglipron administered orally |
Administered orally |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Plasma PK parameters for aleniglipron including, but not limited to AUC0-t
Time Frame: Baseline to Day 3
|
Baseline to Day 3
|
|
Plasma PK parameters for aleniglipron including, but not limited to AUC0-inf
Time Frame: Baseline to Day 3
|
Baseline to Day 3
|
|
Plasma PK parameters for aleniglipron including, but not limited to Cmax
Time Frame: Baseline to Day 3
|
Baseline to Day 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Study Registration Dates
First Submitted
November 13, 2026
First Submitted That Met QC Criteria
November 13, 2026
First Posted (Actual)
November 18, 2026
Study Record Updates
Last Update Posted (Actual)
November 18, 2026
Last Update Submitted That Met QC Criteria
November 13, 2026
Last Verified
November 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GSBR-1290-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.